Sinha Vikas's Form 4 filing
Kalaris Therapeutics, Inc. (KLRS) · filed Oct 24, 2022
- Accession no.
- 0000899243-22-034060
- Filed
- Oct 24, 2022
- Trade date
- Oct 19, 2022
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $13.6K. It was filed 5 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0000899243-22-034261 (Oct 26, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sinha VikasCIK 0001337845 | Director, Officer (See Remarks), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 19, 2022 | Common Stock | SSaleDisposed | −1,449 | $9.36F2 | −$13,562.64 | 1,036,775 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President and Chief Financial Officer